TIDMPRTC
PureTech Health PLC
14 October 2021
14 October 2021
PureTech Health plc
PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi
as Chief Legal Officer and Corporate Secretary
Extensive legal experience with private and public biotech
companies, including Biogen, IVAX Corporation and Cell Signaling
Technology
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, announced
today that its Founded Entity, Vedanta Biosciences ("Vedanta") has
appointed Simona Levi, Ph.D., J.D., as Chief Legal Officer and
Corporate Secretary. Dr. Levi brings over 25 years of United States
and international legal experience with private and public
companies across the life sciences industry focusing on complex
transactions, intellectual property law and litigation, and
corporate governance.
Dr. Levi joins Vedanta from Cell Signaling Technology (CST),
Inc., where she served as the general counsel and corporate
secretary managing all legal matters including assisting with the
formation of the company's global subsidiaries and structuring all
financial transactions. Dr. Levi spent more than 25 years working
as legal counsel for corporate and intellectual property matters in
the life sciences industry. Most notably, she was a partner at the
law firm McDermott Will & Emery, served as director of
neurology for Biogen, and was a senior IP counsel for IVAX
Corporation.
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer
and Corporate Secretary
Extensive legal experience with private and public biotech
companies, including Biogen, IVAX Corporation and Cell Signaling
Technology
CAMBRIDGE, MA, October 14, 2021 - Vedanta Biosciences , a
clinical-stage company that is developing a potential new category
of oral therapies based on defined bacterial consortia, today
announced the appointment of Simona Levi, Ph.D., J.D., as Chief
Legal Officer and Corporate Secretary. Dr. Levi brings over 25
years of United States and international legal experience with
private and public companies across the life sciences industry
focusing on complex transactions, intellectual property law and
litigation, and corporate governance.
"Simona's deep legal experience and proven track record in the
life sciences industry will be critical as we execute on our vision
to enable a new class of drugs in the microbiome field," said
Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of
Vedanta Biosciences. "We are excited to welcome Simona to the
Vedanta team and look forward to her contributions."
Dr. Levi joins Vedanta from Cell Signaling Technology (CST),
Inc., where she served as the general counsel and corporate
secretary managing all legal matters including assisting with the
formation of the company's global subsidiaries and structuring all
financial transactions. Dr. Levi spent more than 25 years working
as legal counsel for corporate and intellectual property matters in
the life sciences industry. Most notably, she was a partner at the
law firm McDermott Will & Emery, served as director of
neurology for Biogen, and was a senior IP counsel for IVAX
Corporation.
Dr. Levi has a B.A. in biochemistry and economics, a Ph.D. in
biochemistry from Rutgers University and a J.D. from the University
of Pennsylvania Law School. Dr. Levi has been a member of the
Massachusetts Bar Association since 1995.
"With the recent activity and interest in the microbiome field,
it has become clear that Vedanta has shown great promise in
pioneering defined bacterial consortia as a new class of
therapeutics," said Dr. Levi. "Vedanta has assembled a talented and
dedicated team and I am thrilled to be joining such a dynamic
company at this pivotal stage of its growth."
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential
new category of oral therapies based on defined consortia of
bacteria isolated from the human microbiome and grown from pure
clonal cell banks. The company's clinical-stage pipeline includes
product candidates being evaluated for the treatment of high-risk
C. difficile infection, inflammatory bowel diseases, advanced or
metastatic cancers, and food allergy. These investigational
therapies are grounded in pioneering research - published in
leading journals including Science , Nature , and Cell - to
identify beneficial bacteria that live symbiotically within the
healthy human gut, fight pathogens and induce a range of potent
immune responses. Vedanta Biosciences controls a foundational
portfolio of more than 40 patents and has built what it believes to
be the world's biggest library of bacteria derived from the human
microbiome. Proprietary capabilities include deep expertise in
consortium design, vast datasets from human interventional studies
and cGMP-compliant manufacturing of oral live biotherapeutic
candidates containing pure, clonally derived bacterial consortia in
powdered form. Vedanta Biosciences was founded by PureTech Health
(Nasdaq: PRTC, LSE: PRTC) and a global team of scientific
co-founders who pioneered Vedanta's modern understanding of the
cross-talk between the microbiome and the immune system.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 25 therapeutics and therapeutic
candidates, including two that have received both U.S. FDA
clearance and European marketing authorization, as of the date of
PureTech's most recently filed Half Year Report and corresponding
Form 6-K. All of the underlying programs and platforms that
resulted in this pipeline of therapeutic candidates were initially
identified or discovered and then advanced by the PureTech team
through key validation points based on the Company's unique
insights into the biology of the brain, immune and gut, or BIG,
systems and the interface between those systems, referred to as the
BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
that relate to Vedanta's future prospects, development plans, and
strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2020 filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the Company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
# # #
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFAESDEFSELS
(END) Dow Jones Newswires
October 14, 2021 07:01 ET (11:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024